来自MSN1 个月
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
TUESDAY, Dec. 17, 2024 (HealthDay News) -- Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase ...
Renal & Urology News1 个月
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
The risk for nonproliferative diabetic retinopathy progression was similar for empagliflozin vs DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...
来自MSN1 个月
Empagliflozin Linked to Lower Risk of Diabetic Retinopathy Progression
Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 ...